Auxly Cannabis Group Inc
TSX:XLY
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/GP
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Valuation Scenarios
If EV/GP returns to its 3-Year Average (2.8), the stock would be worth CA$0.15 (11% upside from current price).
| Scenario | EV/GP Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 2.6 | CA$0.14 |
0%
|
| 3-Year Average | 2.8 | CA$0.15 |
+11%
|
| 5-Year Average | 3.9 | CA$0.21 |
+52%
|
| Industry Average | 3.2 | CA$0.17 |
+23%
|
| Country Average | 6.6 | CA$0.35 |
+158%
|
Forward EV/GP
Today’s price vs future gross profit
Peer Comparison
| Market Cap | EV/GP | P/E | ||||
|---|---|---|---|---|---|---|
| CA |
|
Auxly Cannabis Group Inc
TSX:XLY
|
184.3m CAD | 2.6 | 4.4 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
804.2B USD | 15.5 | 39 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.4B USD | 8.8 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 6.3 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
212.4B GBP | 6.4 | 27.7 | |
| CH |
|
Novartis AG
SIX:NOVN
|
216.3B CHF | 7.2 | 20.3 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
274.6B USD | 5.8 | 15 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 160.7 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 5 | 11.3 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
149.3B USD | 4.2 | 19.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
115.9B USD | 4.2 | 16.4 |
Market Distribution
| Min | 0.1 |
| 30th Percentile | 3.8 |
| Median | 6.6 |
| 70th Percentile | 10.6 |
| Max | 259 067.6 |
Other Multiples
Auxly Cannabis Group Inc
Glance View
Auxly Cannabis Group, Inc. engages in developing, manufacturing, and distributing branded cannabis products for wellness and recreational consumers. The company is headquartered in Toronto, Ontario. The company went IPO on 2001-08-20. The firm is focused on developing, manufacturing and distributing branded cannabis products for wellness and recreational consumers. The firm's segments include Canadian cannabis operations and South American cannabis operations. Both segments are engaged in the cultivation and sale of cannabis products in respective regions. The company provides various products, including vaporizers, edibles, pre-rolls, capsules and oils and concentrates. The firm's brands include Back Forty, Foray, Dosecann and Kolab Project. The company is also a licensed producer of Cannabis 2.0 as well as Cannabis 1.0 products. The firm's subsidiaries include Dosecann LD Inc., Kolab Project Inc., Robinson's Cannabis Inc., Robinson's Outdoor Grow Inc. and Inverell S.A.
